BioSig Technologies Inc SEC Filings

Streamex Corp. entered a Second Amendment to its Secured Convertible Debenture Purchase Agreement with Yorkville, supporting a program for up to $100,000,000 in convertible debentures. The company plans to issue a $25,000,000 first convertible debenture that matures in 24 months and bears 4.00% interest, rising to 18.00% upon default. Closing is conditioned on maintaining Nasdaq listing approval.

The debenture is convertible at the lower of a fixed price set at 125% of the VWAP prior to first closing (with a one‑time downward reset tied to the Resale Registration Statement’s effectiveness window) or 97.0% of the lowest daily VWAP over the prior three trading days, with a $4.00 floor, subject to anti‑dilution adjustments and a 19.99% cap under Nasdaq rules. At least $25.1 million of proceeds—$12.6 million at first closing and $12.5 million at second closing—must be deposited to purchase Allocated Vaulted Gold Bullion as collateral. Obligations are secured by a first‑priority lien on substantially all assets. The securities will be issued in reliance on Section 4(a)(2) and/or Regulation D.

Frank Giustra, a director and 10% owner of Streamex Corp. (STEX), reported multiple purchases of the issuer's common stock executed on 07/25/2025 and 08/14/2025. The filings show four purchases on July 25 totaling 50,000 shares at prices between $4.64 and $4.72, and a later purchase on August 14 of 128,205 shares at $3.90, bringing the reported beneficial ownership to 178,205 shares. The shares are held indirectly through Sestini & Co., an entity controlled by the reporting person, as disclosed in the explanation. There are no derivative securities reported on this form. The document is signed by the reporting person on 09/15/2025.

The filing is an initial Form 3 by Frank Giustra reporting indirect beneficial ownership in Streamex Corp. (STEX). Mr. Giustra beneficially holds 17,193,640 Exchangeable Shares that are exchangeable into Common Stock of the issuer. Approximately 5.01% of the Exchangeable Shares are currently exchangeable into Common Stock, with the remaining Exchangeable Shares becoming exchangeable upon a pending stockholder approval expected within 60 days. Nasdaq rules limit exchanges to 19.9% of outstanding Common Stock until stockholder approval is obtained.

BioSig Technologies, Inc. (BSGM) filed an Form 8-K dated September 5, 2025 reporting corporate governance actions. The filing lists Item 5.03 (submission of matters to a vote of security holders) and includes two exhibits: a Ninth Certificate of Amendment (Exhibit 3.1) and an Incentive Plan Amendment (Exhibit 10.1). The cover page also references an Inline XBRL interactive data file. The form is signed by Karl Henry McPhie, Chief Executive Officer.